慢性髓性白血病研究现状

 近年来对慢性髓性白血病（CML）发病的分子机制研究取得了较大进展，推动了临床治疗的发展。bcr-abl酪氨酸激酶活性异常是CML发病的主要分子机制，在DNA、mRNA、蛋白质、细胞水平不同层次上选择治疗药物，推动了分子靶向性药物治疗的开发，其中酪氨酸激酶抑制剂甲璜酸伊马替尼的出现成为CML药物治疗的里程碑。同时造血干细胞移植技术的完善以及其他治疗手段的应用，为CML的根治提供了更多的机会。现就有关CML发病的分子机制和治疗进展作一综述。

The study status of chronic myeloid leukemia

The study of chronic myeloid leukemia has yielded many insights into the molecular pathology of leukemia in recent years. BCR-ABL fusion oncoprotein with constitutive activation of tyrosine kinase is central to the pathogenesis of the disease. Target to DNA, mRNA or protein of bcr-abl results in research and development of molecular-target drugs, of which imatinib mesylate as a tyrosine kinase inhibitor has proved remarkably effective. Allogeneic stem cell transplantation and other therapies provide more chance to cure for the patients with chronic myeloid leukemia. This review presents the status of basic and clinical study in chronic myeloid leukemia.